Implementing an intensified antibiotic stewardship programme targeting daptomycin use in orthopaedic surgery: a cost–benefit analysis from the hospital perspective

Infection

Volumn 44, Issue 3, 2016, Pages 301-307

  Borde, Johannes P ^a,c   Nussbaum, Sarah ^b   Hauser, Stefanie ^b   Hehn, Philip ^c   Hübner, Johannes ^d   Sitaru, Gabriela ^f   Köller, Sebastian ^g   Schweigert, Bruno ^g   deWith, Katja ^e   Kern, Winfried V ^c   Kaier, Klaus ^c  

^a Ortenauklinikum Achern   (Germany)

^b Zentralapotheke   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f MVZ Labor Clotten   (Germany)

^g Ortenauklinikum Offenburg Gengenbach   (Germany)

Author keywords

Antibiotic stewardship; Cost benefit analysis; Orthopaedic surgical care; PJI

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN; FLUCLOXACILLIN; PENICILLIN DERIVATIVE;

ANTIBIOTIC STEWARDSHIP PROGRAM; ANTIBIOTIC THERAPY; ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG USE; ENDOPROSTHESIS; HEALTH CARE PLANNING; HEALTH PROGRAM; HOSPITAL; HUMAN; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; ORTHOPEDIC SURGERY; PERIPROSTHETIC JOINT INFECTION; PRACTICE GUIDELINE; STAPHYLOCOCCUS INFECTION; TIME SERIES ANALYSIS; TISSUE CULTURE; ADVERSE EFFECTS; ECONOMICS; HOSPITAL PHARMACY; PROSTHESIS-RELATED INFECTIONS; STANDARDS;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DAPTOMYCIN; HUMANS; ORTHOPEDIC PROCEDURES; PHARMACY SERVICE, HOSPITAL; PROSTHESIS-RELATED INFECTIONS;

EID: 84945174541     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0854-y     Document Type: Article

References (22)

1. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–9.
2. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.
3. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013;4:CD003543.
4. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect. Dis Clin North Am. Elsevier Ltd; 2011; 25: 245–60.
5. Campbell KA, Stein S, Looze C, Bosco JA. Antibiotic stewardship in orthopaedic surgery: principles and practice. J Am Acad Orthop Surg. 2014;22:772–81.
6. Cruz-Rodríguez NC, Hernández-García R, Salinas-Caballero AG, Pérez-Rodríguez E, Garza-González E, Camacho-Ortiz A. The effect of pharmacy restriction of clindamycin on Clostridium difficile infection rates in an orthopedics ward. Am J Infect Control. 2014;42:e71–3.
7. Campbell KA, Phillips MS, Stachel A, Bosco JA, Mehta SA. Incidence and risk factors for hospital-acquired Clostridium difficile infection among inpatients in an orthopaedic tertiary care hospital. J Hosp Infect. 2013;83:146–9.
8. Catanzano A, Phillips M, Dubrovskaya Y, Hutzler L, Bosco J. The standard one gram dose of vancomycin is not adequate prophylaxis for MRSA. Iowa Orthop J. 2014;34:111–7.
9. Norton TD, Skeete F, Dubrovskaya Y, Phillips, Bosco JD, Mehta SA. Orthopedic surgical site infections: analysis of causative bacteria and implications for antibiotic stewardship. Am J Orthop (Belle Mead. NJ). 2014;43:E89–92.
10. Oliveira PR, Paula AP, Dal-Paz K, Felix CS, Rossi F, Silva JS, et al. Impact of restriction of cefepime use on the antimicrobial susceptibility of Gram-negative bacilli related to healthcare-associated infections in an orthopedic hospital. Infect Drug Resist. 2011;4:149–54.
11. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1–10.
12. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27(61–5):e1.
13. Sculco TP. The economic impact of infected total joint arthroplasty. Instr Course Lect. 1993;42:349–51.
14. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645–54.
15. Borde JP, Litterst S, Ruhnke M, Feik R, Hübner J, deWith K, et al. Implementing an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a 200-bed community hospital in Germany. Infection. 2014;43:45–50.
16. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309.
17. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2012;56:e1–25.
18. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373–80.
19. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med. 2005;20:777–86.
20. Borde JP, Kaier K, Steib-Bauert M, Vach W, Geibel-Zehender A, Busch H, et al. Feasibility and impact of an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center. BMC Infect Dis. 2014;14:201.
21. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33:338–45.
22. Dik J-WH, Vemer P, Friedrich AW, Lo-Ten-Foe JR, Sinha B, et al. Financial evaluations of antibiotic stewardship programs-a systematic review. Front Microbiol. 2015;6:317.